Grant Bogle

Mr. Bogle brings nearly four decades of proven leadership in building and growing biotechnology companies to the Nuvalent Board. Throughout his career, he has served in senior leadership roles at several specialty pharmaceutical and biotechnology companies and worked alongside oncologists as part of the leadership of US Oncology, the largest network of community oncology practices in the United States. He has a proven track record of success in the field of oncology and has guided numerous products from early-stage development to commercialization. Most recently, Mr. Bogle was the Chief Executive Officer at Epizyme, Inc., and oversaw the 2022 acquisition of the company by Ipsen. Prior to that, Mr. Bogle was Senior Vice President and Chief Commercial Officer of TESARO, which was acquired by GlaxoSmithKline in 2018. Earlier, he served as Senior Vice President of Pharmaceutical and Biotech Solutions at McKesson Specialty Health/U.S. Oncology.

Mr. Bogle currently serves on the board of Myrobalan Therapeutics and the American School for the Deaf in Hartford, CT. He previously served on the Board of Epizyme prior to his appointment to CEO and functioned as a member of the compensation committee. Mr. Bogle earned a B.A. in Economics from Dartmouth College, an M.B.A from Columbia University and was a 2020 Fellow in the Advanced Leadership Initiative at Harvard University.